{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"5.6","value":"0.99"}]}],"title":"Time to first response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"26.8","value":"6.95"}]}],"title":"Time to best response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment.","dispersionType":"Full Range","groups":[{"description":"Participants administered with daratumumab 16 mg/kg on Day 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 milligram (mg) on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT population analysis set included all enrolled participants who signed the informed consent during Phase 2. Here, 'N' (overall number of participants analyzed) signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Phase 2: Time to Response","type":"SECONDARY","unitOfMeasure":"Months"}